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Abstract:
The United States, the European Union and Japan comprise 75% of the world’s
pharmaceutical market and generate 90% of all pharmaceutical research. Rec-
ognizing the need for and beneﬁts of harmonized testing standards the United
States, the European Union and Japan formed a joint initiative between the
industry and regulators called the International Conference on Harmonization
(ICH). The ICH initiative has been underway for over a decade now. This paper
will examine the disparate pharmaceutical regulatory regimes of the U.S., the
EU, and Japan and will explore the ICH eﬀort and its progress thus far.
Part I of this paper overviews the current regulation of new pharmaceuticals in the United States, the
European Union, and Japan. Based on these overviews, it will be apparent that the regulatory agencies
of these three regions have already made some progress in harmonizing international standards. Part II
explores the forces at work behind harmonization and discusses the potential beneﬁts of pharmaceutical
harmonization. Part III explains the ICH initiative including the mechanics of the ICH process and its
implementation in the three ICH regions. Part IV of the paper addresses problems inherent in, and barriers
to the achievement of the goals of the ICH. Finally, Part V of the paper discusses the accomplishments of
the ICH thus far and evaluates its impact on the drug review process.
1INTRODUCTION
Drug regulatory agencies share the common goal of allowing safe and eﬀective drugs to reach the market.
Despite this, drug regulators have acted in isolation in developing standards for evaluating the quality, safety
and eﬃcacy of drugs. Accordingly, the detailed technical requirements of drug testing standards have varied
signiﬁcantly from country to country. As a result of this, new drugs poised for international marketing have
been subject to multiple and duplicate testing. The time and costs associated with this multiple testing
and unnecessary regulation have been overwhelming.1 This results in higher prices, delays in treatment
and the unavailability of some drugs in some markets.2 Harmonization of the scientiﬁc requirements of
pharmaceutical regulatory schemes worldwide will reduce duplication of tests and speed the approval of
drugs throughout the world.
1David W. Jordan, International Regulatory Harmonization: A New Era in Prescription Drug Approval, 25 VAND. J.
TRANSNAT’L L. 471, 491 (1992).
2Ileana Dominguez-Urban, Harmonization in the Regulation of Pharmaceutical Research and Human Rights: The Need to
Think Globally, 30 CORNELL INT’L L.J. 245, 245 (1997).
2The United States, the European Union and Japan comprise 75% of the world’s
pharmaceutical market and generate 90% of all pharmaceutical research.3 Rec-
ognizing the need for and beneﬁts of harmonized testing standards the United
States, the European Union and Japan formed a joint initiative between the
industry and regulators called the International Conference on Harmonization
(ICH).4 The ICH initiative has been underway for over a decade now. This pa-
per will examine the disparate pharmaceutical regulatory regimes of the U.S.,
the EU, and Japan and will explore the ICH eﬀort and its progress thus far.
Part I of this paper overviews the current regulation of new pharmaceuticals in the United States, the
European Union, and Japan. Based on these overviews, it will be apparent that the regulatory agencies
of these three regions have already made some progress in harmonizing international standards. Part II
explores the forces at work behind harmonization and discusses the potential beneﬁts of pharmaceutical
harmonization. Part III explains the ICH initiative including the mechanics of the ICH process and its
implementation in the three ICH regions. Part IV of the paper addresses problems inherent in, and barriers
to the achievement of the goals of the ICH. Finally, Part V of the paper discusses the accomplishments of
the ICH thus far and evaluates its impact on the drug review process.
I. CURRENT REGULATION OF PHARMACEUTICAL PRODUCTS
A. The United States
1. Overview: The FDA and the Food Drug and Cosmetic Act
3Rosemarie Kanusky, Pharmaceutical Harmonization: Standardizing Regulations Among the United States, The European
Economic Community, and Japan, 16 HOUS. J. INT’L L. 665, 667 (1994).
4Alessandra Cortez, Introducing the International Conference on Harmonization Guidelines Into the World Trade Organiza-
tion: A Strategy to Remove Technical Trade Barriers for Pharmaceutical Products, The International Commercial Diplomacy
Project, at http://www.commercialdiplomacy.org/ma projects/cortez.htm (Spring 2002).
3“The sale and distribution of pharmaceuticals in the United States is primarily controlled by the Food, Drug,
and Cosmetic Act, which is interpreted and enforced by the Food and Drug Administration (FDA).”5 The
regulatory and scientiﬁc body that oversees the development and marketing of all new drugs is the FDA’s
Center for Drug Evaluation and Research (CDER).6
The FDA oversees what is generally regarded as the world’s most demanding drug regulation and approval
process.7 In the past, critics of the FDA have asserted that the rigors and ineﬃciencies of the FDA’s review
process for new drugs have resulted in fewer, and the delayed availability of, new drugs.8 However, a good
deal has changed in the past decade to accelerate the speed with which the FDA approves new drugs.9
Much of the FDA drug review process has been reformed under the Food and Drug Administration Modern-
ization Act of 1997 (FDAMA) and the reauthorized Prescription Drug User Fee Act (PDUFA).10 “[W]hat
made FDAMA particularly signiﬁcant was its new philosophical approach, which redeﬁned and broadened
FDA’s original character as a self-reliant public health law enforcement agency.”11 Prior to the enactment of
FDAMA, the FDA’s mission was focused primarily on the following overall objectives: “1) a timely review
of regulated products, 2) the protection of public health by ensuring that food and cosmetics are safe and
properly labeled, 3) ensuring that human and veterinary drugs are safe and eﬀective, 4) providing a reason-
able assurance of the safety and eﬀectiveness of medical devices, and 5) public protection form electronic
product radiation.”12
FDAMA added two additional objectives to the FDA’s mission: to “participate... with representatives in
5Kanusky, supra note 3, at 668.
6MARK MATHIEU, NEW DRUG APPROVAL IN THE UNITED STATES 64 (2002/2003 ed., PAREXEL Interna-
tional Corporation 2002).
7Id. at 1.
8Jordan, supra note 1, at 471.
9Mathieu, supra note 6, at 1.
10Mathieu, supra note 6, at 63.
11Linda A. Suydam & Milan J. Kubic, FDA’s Implementation of FDAMA: An Interim Balance Sheet, 56 FOOD & DRUG
L.J. 131, 131 (2001).
12Id.
4other countries to reduce the burden of regulation, harmonize regulatory requirements, and achieve ap-
propriate reciprocal agreements;” and to “carry out [its mission] in consultation with experts... and in
cooperation with consumers, users, manufacturers, importers, packers, distributors, and retailers of regu-
lated products.”13
Additionally, in 1997, the Prescription Drug User Fee Act (PDUFA I) of 1992 was reauthorized for another
5 years (PDUFA II).14 Under PDUFA I, the FDA had agreed to meet accelerating time frames for reviewing
certain human drugs and biological products in return for fees paid by drug manufacturers.15
In addition to shorter time frames under PDUFA II, the FDA has agreed to a new set of procedural goals
intended to enhance the quality and eﬃcacy of the drug development process. These goals included “speci-
fying time-limits for such activities as scheduling technical guidance and pre-submission meetings with the
product sponsors, resolution of major disputes and clinical holds, and rapid handling of other procedural,
processing and management issues.”16 PDUFA I and PDUFA II have been extremely successful, with the
FDA meeting or exceeding nearly all of their performance goals. The median total approval time for new
drug applications has decreased from 23.8 months in 1990 to 11.6 months by the end of 1999. Median
approval time of priority applications has dropped from over 13 months in 1990 to 6 months by 1999.17 Due
to their tremendous success, negotiations are underway to put PDUFA III into eﬀect in September 2003.18
The current evolutionary phase of new drug regulation in the United States is being driven by a focus on
international harmonization and risk management.19 The following are examples of changes that have been






18Note that the FDA’s approval of large number of new drug in record time has not gone without criticism. The agency faced
considerable criticism after three approved drugs (Redux, Posicor, and Duract) were withdrawn from the market in 1997 and
1998. The primary criticism was that the agency’s focus on speed of approval came at the expense of drug safety. Mathieu,
supra note 6, at 1.
19Mathieu, supra note 6, at 1.
5came a regulatory option to the NDA for companies seeking FDA approval of a new drug.20 Additionally,
in response to concerns regarding drug safety, the CDER has integrated “ risk management” considerations
into NDA reviews.21 In doing so, the CDER is asking drug sponsors and its reviewers what additional steps
can be taken to make a newly approved drug as safe as possible in the marketplace. Risk management
alternatives that the CDER is evaluating more and more in new drug reviews include restricted distribution
programs, educational programs, patient package inserts, special surveillance systems, and safety-related
communications.22 Finally, in acknowledgement that in the face of speedier and rising numbers of drug
approvals there is a need for a particularly well-conceived post-marketing drug surveillance program, CDER
oﬃcials announced a reinvigorated post-marketing drug surveillance program under a newly named Oﬃce of
Post-Marketing Drug Risk Assessment (OPDRA).23 Nevertheless, while several factors have inﬂuenced U.S.
drug approval in recent years, the fundamentals of the new drug approval process remain intact within the
provisions of the Food, Drug and Cosmetic Act (FD&C Act).24
2. New Drug Development and the Drug Approval Process
a) Pre-clinical Testing
“Because of the costs and risks inherent in using an untested drug in clinical testing, [...] drug sponsors
do not leap headlong into a clinical program once they have identiﬁed a promising compound.”25 Before
beginning clinical testing, a drug sponsor must provide information demonstrating that “the company can
manufacture the drug, descriptions of the proposed clinical trials, and data establishing that the drug is
20Mathieu, supra note 6, at 1.
21Mathieu, supra note 6, at 2.
22Mathieu, supra note 6, at 2.
23Mathieu, supra note 6, at 2.
24Mathieu, supra note 6, at 3.
25Mathieu, supra note 6, at 5.
6reasonably safe for use in initial, small-scale, clinical studies.”26 Depending on whether the compound
has been studied or marketed previously, there may be several alternative ways for accomplishing this last
requirement. The sponsor may: (1) compile existing non-clinical data derived from past in vitro or animal
studies on the compound; (2) compile data from previous clinical testing or marketing of the drug in the U.S.
or another country who’s population is similar to that of the United States; or (3) undertake new pre-clinical
studies.27
For drugs whose clinical safety and eﬃcacy have not been established in the past, the ﬁrst major step towards
regulatory approval is pre-clinical in vitro and in vivo animal testing.28 From the pre-clinical stage, the FDA
requires that sponsors develop a pharmacological proﬁle of the drug, determine the acute toxicity of the drug
in at least two species of animals, and conduct short-term toxicity studies whose duration is based on the
duration of the proposed clinical studies.29
Because pre-clinical drug development does not involve human exposure to an experimental compound,
drug developers have considerable ﬂexibility in manufacturing, shipping, and testing experimental drugs.30
Practically the only regulatory limitation facing sponsors conducting pre-clinical studies are the general
animal welfare provisions in current federal and state animal protection statutes and regulations and the
FDA requirement that in order to ship a drug intended solely for tests in vitro or in animals used only for
laboratory research purposes be labeled as follows: “Caution: Contains a new drug for investigational use
only in laboratory research animals, or for tests in vitro. Not for use in humans.”31
When a drug sponsor is compiling safety data that it will submit to the FDA, the Good Laboratory Practice
26Mathieu, supra note 6, at 5.
27Mathieu, supra note 6, at 5.
28Mathieu, supra note 6, at 5.
29Mathieu, supra note 6, at 5.
30Mathieu, supra note 6, at 5.
31Mathieu, supra note 6, at 6.
7(GLP) regulations apply. The FDA requires the use of GLP standards to ensure the quality of animal testing
and of the data in which it results.32
b) The IND Application and FDA Review of the IND
When a drug sponsor deems that it has adequate data that demonstrates that the new drug has a high
degree of promise in treating a particular disease and is suﬃciently safe for initial small-scale clinical trials,
the sponsor assembles and submits an Investigational New Drug (IND) application to the FDA.33 The NDA
is the means by which the drug sponsor obtains an exemption from the statutory requirement that bans the
shipment of unapproved drugs in interstate commerce.34
In the IND, the sponsor reports: (1) the results of pre-clinical testing and an analysis of the implications of
these results for human pharmacology; (2) an analysis of the drug’s chemical composition and the quality
control procedures used in producing the compound; and (3) protocols explaining the drug sponsor’s plans for
the initial-stage clinical studies proposed in the IND, and information describing the relevant qualiﬁcations
of the investigators who will carry out these studies.35
Upon submitting the IND application, the sponsor must wait 30 days to allow the FDA to review the appli-
cation. The FDA’s review of an IND involves:
32Mathieu, supra note 6, at 6.
33Mathieu, supra note 6, at 6.
34Mathieu, supra note 6, at 6.
35In an attempt to stop the wave of Phase I studies moving to European nations (resulting from the impression that European
countries generally have less demanding standards for initial stage clinical research), in November of 1995, the FDA “clariﬁed”
its IND content requirements. “Speciﬁcally, the agency established its willingness to accept toxicology data summaries and line
listings based upon sponsors’ unaudited draft toxicological reports of completing animal studies in INDs for Phase 1 studies. By
accepting these summaries and listings based on unaudited draft reports, and permitting companies to update this information
120 days after trials are initiated, the FDA, in eﬀect, permits sponsors to begin phase 1 trials months earlier than in the past.”
Mathieu, supra note 6, at 6.
8♣
Pharmacology/Toxicology Review—The results of the animal pharmacology and toxicity
data are reviewed by a pharmacologist who attempts to relate these results to human pharmacology.
♣ Chemistry Review—The sponsor’s manufacturing processes and control procedures are evaluated by a
chemist to make certain that the compound is reproducible and in its pure form. Additionally, the chemist
compares the drug’s characterization, chemical structure, and impurity proﬁle to that of other drugs known
to be toxic.
♣ Clinical Review—Clinical protocols are evaluated by a reviewing medical oﬃcer (generally a physician)
to make sure that test subjects will not be exposed to unreasonable risks during the clinical trials, and that
Phase 2 and Phase 3 trials are satisfactory in design.36
If the FDA determines that certain clinical trials may not commence, “the agency contacts the sponsor within
the 30-day period to initiate what is called a “clinical hold”-the delay of the clinical trial until potential
problems of unanswered questions are addressed.”37 If the FDA does not respond to the applicant within 30
days, the sponsor may begin clinical trials pursuant to the standards set forth in the IND application and
FDA regulations.38 Thus, the agency does not literally approve an IND, but allows clinical testing to begin
through its “administrative silence.”39
c) Clinical Trials
Clinical trials embody the most critical and demanding phase in the drug development process. “If a drug
36Mathieu, supra note 6, at 7.
37Mathieu, supra note 6, at 7.
38Jordan, supra note 1, at 479.
39Mathieu, supra note 6, at 7.
9survives the rigors of clinical testing, the FDA’s ultimate approval decision will be based primarily upon
data derived from these studies.”40
The rise in clinical development times was the dominant regulatory controversy of the mid-1990s. The
industry maintained that the relentless rise in clinical development times was extremely prohibitive.41 This,
along with changes in the competitive environment for pharmaceuticals, helped to accelerate several trends,
including industry eﬀorts to streamline their clinical development programs and to enhance their clinical trial
eﬀorts internationally. This reality may also have been a motivation behind a new FDA initiative to better
deﬁne the clinical trial data required for drug approval.42 In an attempt to assist sponsors, in May of 1998,
the FDA released guidance entitled, Providing Clinical Evidence for Human Drug and Biological Products,
which supplied the agency’s latest views on the “quantitative and qualitative” standards for establishing
drug eﬀectiveness.43
Clinical trials for diﬀerent drugs are usually similar in structure. “Since researchers may know little about a
new compound prior to its use in humans, testing the drug through serially conducted studies permits each
phase of clinical development to be carefully designed to use and build upon the information obtained from
the research phase preceding it.”44 Clinical investigations most often proceed in three phases.
Phase 1 begins with initial tests of the new drug on normal human volunteers. Low doses of the drug are
administered to 20 to 80 subjects.45 The purpose of this phase is to determine the drug’s toxicity, and obtain
other pharmacological information.46
40Mathieu, supra note 6, at 7.
41Mathieu, supra note 6, at 7.
42Mathieu, supra note 6, at 7.
43Mathieu, supra note 6, at 8.
44Mathieu, supra note 6, at 8.
45Mathieu, supra note 6, at 8.
46Jordan, supra note 1, at 480. (Phase I allows the sponsor to evaluate the drug’s pharmacology and pharmokinetics,
mechanism of action in humans, side eﬀects (of various doses), the optimal route of administration, and the safe dosage range)
Mathieu, supra note 6, at 8.
10Phase II is essentially an extension of Phase I, except in this phase the primary consideration is whether
the drug is eﬀective.47 Clinicians conduct controlled studies on 100 to 200 patients who suﬀer from the
condition that the drug is intended to treat. In addition to providing indication of the drug’s eﬀectiveness
in its projected use, it provides additional safety data. Furthermore, the results of phase II studies can
determine the foundation for chief aspects of phase III study design.48
Next is Phase III. Not only is phase III the longest and most extensive phase of clinical testing, but it is also
the most time consuming part of the entire drug approval process. The purpose of Phase III is to “study
the circumstances under which physicians prescribe the drug for their patients.”49 This phase will only
commence if the data from the previous two phases provides suﬃcient assurance that the drug is safe and
eﬀective and that the potential beneﬁts of the drug outweigh the potential risks of a larger clinical trial.50
Phase III involves the use of the drug on an appreciably larger groups of patients (several hundred to several
thousand) who suﬀer from the condition that the drug is intended to treat. Because some of the Phase III
trials (known as “pivotal” trials) will serve as the primary basis for the drug’s approval, these studies have
to meet more exacting standards.51
d) The New Drug Application
Upon successful completion of the IND process, the sponsor typically ﬁles a New Drug Application (NDA).52
“Since 1938, the new drug application has been the vehicle through which drug sponsors formally propose
that the FDA approve a new pharmaceutical for sale and marketing in the United States.”53 NDAs generally
47Jordan, supra note 1, at 480.
48Mathieu, supra note 6, at 8.
49Jordan, supra note 1, at 480.
50Jordan, supra note 1, at 480.
51Mathieu, supra note 6, at 8.
52Jordan, supra note 1, at 481.
53Mathieu, supra note 6, at 8.
11consist of thousands of pages of clinical and non-clinical data and analysis derived from “adequate tests by
all methods reasonable applicable.”54
However, in August 2001, the ICH produced the Common Technical Document (CTD).55 This now provides
another option for companies seeking FDA approval to market new drugs in the U.S. During the “transition
period,” which will last until July 2003, companies have the choice of submitting U.S. marketing dossiers
in either the CTD or the NDA format.56 Starting July 2003, the FDA will highly recommend that U.S.
marketing dossiers be submitted in CTD format.57 The FDA, however, will not be able to make this a
formal requirement until it undertakes a comprehensive revision of its NDA regulations.58 It is noteworthy
that while the CTD may diﬀer from the NDA in format, it does not diﬀer in content. Furthermore, the
submission standards needed to obtain FDA approval will also not be aﬀected by the move to the CTD
format.59
Regardless of which format is used, the FDA marketing dossier for a new drug is extensive. The application
must provide an exhaustive review of essentially all of the information the sponsor possesses about the drug.
The agency reviewers need to have suﬃcient data and information to make numerous key determinations,
including: “(1) whether the drug is safe and eﬀective in its proposed use(s), and whether the beneﬁts of the
drug outweigh its risks; (2) whether the methods used in manufacturing the drug and the controls used to
maintain the product’s quality are adequate to preserve its identity, strength, and purity; and (3) whether
the drug’s proposed labeling is appropriate and, if not, what the drug’s labeling should contain.”60
Additionally, the CDER has expanded its technical infrastructure such that it can accept electronic NDAs
54Jordan, supra note 1, at 481.
55Mathieu, supra note 6, at 9.
56Mathieu, supra note 6, at 9.
57Mathieu, supra note 6, at 9.
58Mathieu, supra note 6, at 9.
59Mathieu, supra note 6, at 9.
60Mathieu, supra note 6, at 9.
12(e-NDAs). The Pharmaceutical industry appears to be embracing the concept of electronic NDAs. Of the
sixty-one NDAs ﬁled in FY2001, 35% were electronic submissions.61
e) The NDA Review Process
The NDA review process has evolved more over the past ten years than any other element of the drug approval
system. “So fundamental were these changes-and the improvements in drug review times that resulted from
them-that CDERs NDA review performance was transformed from one of the most harshly criticized of FDA
activities into what was perhaps the agency’s best defense against regulatory reform proposals advanced in
the mid-1990s.”62
The motivating forces behind this development were PDUFA I and II, and the changes that the CDER
put into practice in order to meet the new review timelines associated with this PDUFA legislation.63 The
CDER introduced tight controls for managing and tracking drug reviews. Additionally, the CDER’s review
divisions were organized into smaller, more therapeutically focused units.64
Once an NDA is submitted, it is passed on to one of CDER’s drug review divisions—speciﬁcally the CDER
drug review division that manages the therapeutic area applicable to the submission.65 Within 45 days of
the NDA’s submissions, FDA reviewers meet to determine whether the application is complete.66 If the ap-
plication is suﬃciently complete, the NDA is “ﬁled,” or in other words, accepted for review. If the reviewers
ﬁnd that the application is deﬁcient, then the FDA ﬁles a refuse-to-ﬁle (RTF) decision and the application
61Mathieu, supra note 6, at 9.
62Mathieu, supra note 6, at 175.
63Mathieu, supra note 6, at 9.
64Mathieu, supra note 6, at 9.
65Mathieu, supra note 6, at 10.
66Mathieu, supra note 6, at 10.
13is returned to the sponsor.67
Upon the ﬁling of an application, the review team starts the “primary review” of the application. During
this evaluation, each member of the review team sifts through volumes of research data and information
applicable to his or her expertise.68 Additionally, the ﬁling decision prompts a division request that FDA
ﬁeld oﬃce to undertake an inspection of the sponsor’s manufacturing facilities.
Once the primary reviews are completed, each reviewer prepares a written evaluation presenting her con-
clusions and recommendations concerning the NDA. Generally the medical reviewer then evaluates and
reconciles the conclusions of the reviewers from the other scientiﬁc disciplines.69
“For NDA’s submitted in FY1998 through FY 2002, the FDA must review performance goals associated
with PDUFA II. The new review goals will diﬀer for ‘priority’ drugs (i.e., drugs representing a signiﬁcant
improvement over market products) and “standard” drugs. A six-month review timeframe will apply to
priority applications during PDUFA II, while the agency has agreed to take action on increasing percentages
of standard applications within 10 months.”70
Upon completion of the review, the CDER issues an action letter (an approval or not-approval letter) which
conveys the results of the review to the applicant. Additionally, it may identify issues or defects that must be
addressed before the application can be approved. Under PDUFA, the CDER has committed to developing
a regulation establishing that a new type of action letter, called a “complete response” letter, will replace
the approval and non-approval letters.71
3) Acceptance of Foreign Data
67Mathieu, supra note 6, at 10.
68Mathieu, supra note 6, at 10.
69Mathieu, supra note 6, at 11.
70Mathieu, supra note 6, at 11.
71Mathieu, supra note 6, at 11.
14Traditionally, the FDA has had a strong bias against accepting foreign data. Recently, however, they have
started accepting non-U.S. clinical data and have recently approved new chemical entities based on trials
conducted exclusively outside of the United States.72
B. The European Union
1. Background
a) The Path to a Uniﬁed Europe
Following WWII, a number of European nations came to believe in the need for a more integrated Europe.
In 1957, six states (Belgium, France, Germany, Italy, Luxembourg, and the Netherlands) singed the Treaty
of Rome, thereby establishing the European Community (EC). Since then, the Community has grown and
the organization now known as the European Union (EU) currently consists of 15 states: Austria, Belgium,
Denmark, Ireland, Finland, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Portugal, Spain,
Sweden and the United Kingdom.73 Considering the desire of other nations to join the EU, the number of
member states is likely to grow.
Since its establishment, the EU’s goal has been the creation of a fully integrated internal market through
the removal of all barriers to the free movement of goods, persons, services and capital.74
72Elizabeth M. Rutherford, The FDA and Privatization–The Drug Approval Process, 50 FOOD & DRUG L.J. 203 203, 222
(1995).
73MONICA LOFGREN & MIA DREESSEN, NEW DRUG APPROVAL IN THE EUROPEAN UNION 3 (PAREXEL
International Corporation 2002/2003 ed. 2002).
74Id.
15b) The Road to the EMEA
“From the European Community’s early days, the national pharmaceutical marketing authorization proce-
dures within the individual Member States constituted a barrier to the free movement of medicinal products
due to diﬀerences in procedures, data requirements, standards and the time taken to reach decisions on
applications.”75 In an eﬀort to eliminate these barriers, European Community Directives were adopted to
institute: “(t)he requirements for pharmaceutical product marketing authorization; (t)he Committee for
Proprietary Medicinal Products (CPMP), consisting of experts from each of the national regulatory agen-
cies; and (t)he multistate procedure, a non-mandatory process for the mutual recognition of pharmaceutical
product licenses issued by the individual national agencies.”76
The hope was that once a company received marketing authorization in one of the European Community
countries, the other member states would recognize this approval and license the product in their respective
countries. “In the unlikely event of disagreement, the case could be referred to the CPMP for a ﬁnal
decision. In reality, however, almost every case using this multistate procedure was referred to the CPMP,
whose decision was not binding on the Member States.”77 In 1987, an additional procedure known as the
“concertation procedure” was introduced. Its introduction reﬂected the European Community’s conviction
that the eﬃcient development and registration of such products was vital to the success of the European
Pharmaceutical industry. While somewhat more successful than the multistate procedure, it had the same
essential problem—speciﬁcally the lack of a binding decision. This meant that companies had to negotiate





16Due to the deﬁciencies of these procedures and lack of progress achieved by assorted legislation that had been
passed, a period of extensive deliberation followed. The result of such deliberation was the creation of the
European Agency for the Evaluation of Medicinal Products. A new CPMP along with two new procedures—
the centralized procedure and the mutual recognition (decentralized) procedure—were incorporated.79
2. Regulatory Agencies
a) The EMEA
The introduction of Europe’s centralized drug approval procedure required the creation of a new European
Agency—the European Agency for the Evaluation of Medicinal products. This agency, generally referred
to as the European Medicines Evaluation Agency (EMEA), or the Agency, began functioning in February
1995.80 The EMEA’s primary responsibilities concern the administration of the centralized procedure.81
While the EMEA does not have a direct role in the technical reviews of the centralized applications, it hosts
the CPMP, which provides the scientiﬁc opinions on centralized applications based on the reviews of assigned
experts.82 The Agency is also in charge of pharmacovigilance83 and Good Manufacturing Practice (GMP)
inspections.84 Unless an application is referred to it for arbitration, the EMEA is not involved in the mutual
recognition procedures.





83Pharmacovigilance is the process of collecting information on adverse drug reactions at the pre and post-marketing stages,
scientiﬁcally evaluating these adverse drug reaction reports, and making the regulatory decisions that result from this analysis.
REPORT TO THE CHAIRMAN, COMMITTEE ON LABOR AND UMAN RESOURCES, U.S. SENATE., U page 23.
84Lofgren & Dreessen, supra note 73, at 18.
173) a permanent secretariat; and 4) three scientiﬁc committees together with their working parties—the
Committee for Proprietary Medicinal Products (CPMP), the Committee for Veterinary Medicinal Products
(CVMP), and the Committee for Orphan Medicinal Products (COMP).85 The Management Board consists
of representatives from all 15-member states, the European Commission, and the European Parliament.86 It
is the governing body of the EMEA and is responsible for budgetary matters and for ensuring co-ordination
of the national resources of the member states.87 An executive director heads the Agency, and the Permanent
Secretariat is the administrative center that provides general and logistical support to the scientiﬁc committed
and for the day-to-day administration of the EMEA.88
The job of the CPMP and the CVMP is to evaluate the scientiﬁc data presented by pharmaceutical companies
and to issue opinions regarding the approvability and labeling of products. Moreover, since the beginning
of the millennium, the EMEA has hosted the Committee for Orphan Medicinal Products (COMP). This
committee is responsible for determining whether drugs should be conferred orphan drug status.89
The majority of the EMEA’s funding is derived from user fees. Presently, 70% of the EMEA’s funding is
obtained from user fees and another 24% is provided from the EU budget. Today, user fees include not only
application-associated fees but also an annual fee and a fee for the scientiﬁc advice procedure as well.90
85Lofgren & Dreessen, supra note 73, at 19.
86Lofgren & Dreessen, supra note 73, at 5.
87Lofgren & Dreessen, supra note 73, at 20.
88Lofgren & Dreessen, supra note 73, at 19.
89Lofgren & Dreessen, supra note 73, at 5.
90Lofgren & Dreessen, supra note 73, at 5.
18b) The CPMP
From an applicant’s point of view, the EMEA’s Committee for Propriety Medic-
inal Products (CPMP) is the EMEA’s most important body because it provides
the agency’s objective, scientiﬁc opinion upon which the European Community
bases its decision on each product application.91
“The EMEA’s Committee for Proprietary Medicinal Products (CPMP) consists
of two members from each member state; these members are elected to renewable
three-year terms. The CPMP selects its chairman from its membership during
a closed session.”92 On the basis of scientiﬁc measures for quality, eﬃcacy, and
safety, an opinion is issued by the CMPM on the approvability of marketing
applications submitted under the centralized procedure. Based on this opinion,
the European Commission decides whether to issue a license for the product.
For each centralized application, the CPMP assigns a rapporteur and often times
also a co-rapporteur from its membership. In addition, the committee appoints
rapporteurs for arbitration cases referred to it under the mutual recognition
procedure. Rapporateurs are also assigned by the CPMP for arbitration cases
referred to it because of diﬀerences in national decisions and for cases in which
the interest of the Community is concerned.93
The actual evaluation of marketing dossiers is performed by experts who are chosen by the rapporteaur.
These experts are selected from an approved list of European experts who are either on the staﬀ of the
national agencies or are “external” European experts. While the CPMP attempts to reach a scientiﬁc
consensus among its members, a majority opinion is suﬃcient when a unanimous decision is not possible.
All decisions subsequently formulated from this CPMP opinion (e.g., a drug’s authorization) are binding on
all Member States.94
The CPMP has created several working groups to assist it with its work. Because of the increased number
of applications requiring review and the increased complexities of the issues being considered, more of the
91Lofgren & Dreessen, supra note 73, at 22.
92Lofgren & Dreessen, supra note 73, at 6.
93Lofgren & Dreessen, supra note 73, at 7.
94Lofgren & Dreessen, supra note 73, at 7.
19CPMP’s workload is being delegated to these working parties. Ultimately, however, the full CPMP must
consider and reach a decision on each issue.95
A procedure growing in signiﬁcance is the scientiﬁc advice procedure. This procedure allows companies to
seek the CMPC’s advice during a product’s development, for a fee. In order to handle this process, the
CMPC has formed an informal CPMP working group called the Scientiﬁc Advice Review Group. While this
group is currently an informal working group, it is likely to be organized as one of the CPMP’s Working
Parties in the future. Additionally, more emphasis will likely be placed on the pre-submission phase in order
to help companies develop their products and submit higher quality applications.96
c) The European Commission
Traditionally, the European Commission is described as performing the following three functions: initiating
proposals for legislation; serving as the guardian of the Treaties; and executing EU policies and actions,
including the pharmaceutical decision-making process.97
“All opinions formed and issued by the EMEA’s CPMP—including decisions to authorize new drugs under
the centralized approval process—must be converted into decisions that are binding on all Member States.”98
Because the CPMP does not have the authority to make binding decisions, the European Commission is
necessary in order to take action to make their decisions binding. With the help of a body called the Standing
Committee (which consists of representatives from all of the Member States), the European Commission
adopts ﬁnal CPMP opinions. When there is serious dissent between the Member States regarding such
95Lofgren & Dreessen, supra note 73, at 7.
96Lofgren & Dreessen, supra note 73, at 7.
97Lofgren & Dreessen, supra note 73, at 31.
98Lofgren & Dreessen, supra note 73, at 30.
20opinions, the EU’s Council of Ministers becomes involved.99 All binding decisions follow a speciﬁc procedure
called the decision-making process, outlined in Regulation (EEC) 2309/93 and in Regulation 1662/95.100
d) National Agencies
“[T]he national agencies throughout Europe continue to play the major role in all matters relating to the
mutual recognition procedure.” The EMEA is only involved in the procedure when an application is referred
to it for arbitration. Moreover, the national agencies continue to register products when the national routes
must be used, such as for line extensions when the ﬁrst application was approved through the old national
routes and for applications for local generic product.101
Furthermore, the national agencies accept responsibility for the maintenance of all products approved and
on the market before the new European Regulatory became eﬀective. Additionally, the Reference Member
State agency is in charge of reviewing new data to sustain marketed products approved through the Mutual
Recognition procedure or the centralized procedure. Finally, the national agencies supply the majority of
the experts engaged in reviewing applications submitted under the centralized route.102
3. Registration Procedures
99Lofgren & Dreessen, supra note 73, at 30.
100Lofgren & Dreessen, supra note 73, at 96.
101Lofgren & Dreessen, supra note 73, at 43.
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21a) The Centralized Procedure
Under the centralized procedure, a single application, a single evaluation administered by the EMEA, and
a single authorization provide direct and simultaneous access to the EU’s 15 Member States. Additionally,
Iceland and Norway have been participating in the centralized process since January 2000.103 The Annex
to Council Regulation 2309/93 established that two classes of medicinal products could contend for the
centralized procedure.104 Products listed in Part A of the Annex must be registered through the centralized
procedure even if marketing of the product is intended in only one member state. On the other hand, spon-
sors of Products in Part B have the option of using either the centralized process or the mutual recognition
process.105
Evidence thus far strongly suggests that the pharmaceutical industry is embracing the centralized procedure.
By the end of the year 2000, 279 applications had been submitted to the EMEA via the centralized procedure.
Of these 279 applications, only one-third involved Part A products (products for which the centralization
procedure is mandatory). Such statistics reveal that drug companies were choosing to use the centralized
procedure for products for which it was not required.106
Part A products are all biotechnology products developed through any of the following processes: “recom-
binant DNA technology; controlled expression of genes coding for biologically active proteins in prokaryotes
and eukaryotes, including transformed mammalian cells; hybridoma and monoclonal antibody methods.”107
Part B includes a number of innovative products, such as new medicinal products derived from human blood
or human plasma, and medicinal products administered by means of a new delivery system which in the
opinion of the agency constitute a signiﬁcant innovation.108
103Lofgren & Dreessen, supra note 73, at 67.
104Lofgren & Dreessen, supra note 73, at 69.
105Lofgren & Dreessen, supra note 73, at 69.
106Lofgren & Dreessen, supra note 73, at 5.
107Lofgren & Dreessen, supra note 73, at 69.
108Lofgren & Dreessen, supra note 73, at 69.
22A rapporteur is the scientiﬁc project leader selected by the CPMP for a given application in the centralized
process. A rapporteur is generally not the primary reviewer for an application but instead serves to organize
the review. The CPMP normally selects both a rapporteur and a co-rapporteur so as to provide for two in-
dependent reviews of an application. Experts whom the rapporteur selects from a list of accepted European
experts perform the actual scientiﬁc review.109
Since the introduction of the centralized procedure, companies by and large have been granted at least one
of their preferences for rapporteur or co-rapporteur. Due to the increase in the number of requests for rap-
porteurs from the same subgroup of Member States and the CPMP’s partiality towards the even distribution
of work among all of the CPMP Member States in rotation, fulﬁlling application requests has been more
diﬃcult.110 This, along with the requirement that a single common drug name be used in all of the 15
Member States and Iceland and Norway, are two limitations associated with the centralized process.111
Under the centralized procedure, scientiﬁc assessment of the application should take no more than 120 days.
At that point, the review clock stops to allow the applicant to respond to a list of CPMP questions. Addi-
tionally, the CPMP will notify the applicant whether the ﬁle is approvable or non-approvable. The CPMP
will then give the company a chance to supply the necessary information and speciﬁed data. Although the
legislation does not specify the duration of this clock stop, the CPMP expects that the clock stop will not
exceed 6 months.112
Following the CPMP’s review of the additional information supplied in response to its questions and com-
ments, the CPMP determines whether there are still unresolved issues.113 “When necessary, the committee
may invite the company to a hearing at the EMEA’s London oﬃces in hopes of reaching a resolution for
109Lofgren & Dreessen, supra note 73, at 77.
110Lofgren & Dreessen, supra note 73, at 8.
111Lofgren & Dreessen, supra note 73, at 70.
112Lofgren & Dreessen, supra note 73, at 8.
113Lofgren & Dreessen, supra note 73, at 8.
23pending issues.”114 Such a hearing takes place by Day 180 after which the CPMP reaches a preliminary
opinion. The committee’s ﬁnal opinion on an application will be issued by day 210, when all of the ad-
ministrative paper work must be ﬁnalized. The CPMP’s opinion must subsequently be submitted to the
European Commission in order for the decision to be made legally binding.115
b) The Mutual Recognition Procedure
Under the new mutual recognition procedure, the national recognition of a product in one Member State
may be “mutually recognized” by another Member State following a speciﬁc request by the applicant and
the submission of an identical ﬁle to the Member States where the applicant wants to market its product.116
If the other Member States mutually acknowledge the ﬁrst approval with or without negotiation, then the
CPMP is not drawn into the procedure. If any of the Member States involved fail to mutually recognize
the product’s original authorization within 90 days, then the case is referred to the CPMP for arbitration,
unless the applicant withdraws the application in the objecting Member State(s). At a standard CPMP
meeting, the committee discusses the pending application and selects a rapporteur for the arbitration process.
Additionally, experts may be appointed from the list of approved European experts to prepare a further
assessment report. The ﬁnal recommendation of the CPMP in arbitration cases is binding on all the Member
States involved in a speciﬁc mutual recognition procedure.117
Unlike the centralized procedure, the mutual recognition procedure has not been very successful. Problems
have arisen primarily from the mutual recognition procedure’s “lack of ownership—that is, no single group
114Lofgren & Dreessen, supra note 73, at 9.
115Lofgren & Dreessen, supra note 73, at 9.
116Lofgren & Dreessen, supra note 73, at 9.
117Lofgren & Dreessen, supra note 73, at 9.
24among all the players involved in the process is accountable for its success or failure.”118 Notwithstanding
the fact that completed review and assessment reports are available from the Reference Member State (the
country that ﬁrst approves the drug), a majority of the Member States nevertheless conduct their own
independent application reviews under the mutual recognition procedure and raise countless questions for
applicants. To provide Member States a chance to resolve issues among themselves, procedures have been set
up through which Member States that are in conﬂict can meet with the Reference Member State to attempt
to settle the unresolved issues. A voluntary group named the Mutual Recognition Facilitation Group has
been formed to discuss issues concerning mutual recognition and to oﬀer “break-out” sessions during which
Member States concerned can discuss problems associated with a speciﬁc application. Applicants also may
be invited to take part in such meetings.119
C. Japan
Considerable changes have taken place in Japan’s drug approval process since the late 1990s. The most
signiﬁcant of these changes include “the creation of the new Ministry of Health, Labor and Welfare (MHLW),
the streamlining of the Japanese NDA review process, Japan’s growing acceptance of foreign-generated
clinical data, and the country’s implementation of several harmonized ICH guidelines that aﬀect both non-
clinical and clinical activities.”120 With such changes Japan has evidenced a desire to make its process more
consistent with those of the world’s other major markets and a desire to eliminate many of the impediments
for new drug development and approval within its country.121
118Lofgren & Dreessen, supra note 73, at 10.
119Lofgren & Dreessen, supra note 73, at 10.
120KEITH B. RUSSELL & W. MICHAEL BREMER, NEW DRUG APPROVAL IN JAPAN 1 (PAREXEL International
Corporation, 2002/2003 ed. 2002).
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251. Japanese Regulatory Authorities
a) The Ministry of Health, Labor and Welfare (MWLW)
The Japanese drug regulatory body is known as the Ministry of Health, Labor and Welfare (MHLW), or
the Koseisho. 122 In addition to being responsible for pharmaceutical regulation in Japan, the MHLW is
responsible for the advancement of social welfare, social security and the public health.123 Of the MHLW’s
eleven bureaus, the main “MHLW bureaus responsible for pharmaceutical regulation are the Pharmaceu-
tical and Medical Safety Bureau (PMBS), the National Institutes of Health Sciences’ Pharmaceutical and
Medical Devices Evaluation Center (PMDEC), and the Organization of Pharmaceutical Safety and Research
(OPSR/KIKO).”124
b) Pharmaceutical and Medical Safety Bureau (PMSB)
The PMSB plays the role of the leader of the Ministry’s drug evaluation and safety functions. Two of
the PMSB’s most signiﬁcant units are the Evaluation and Licensing division and the Safety Division.125
The Evaluation and Licensing division is responsible for “the review and approval of manufacturing, re-
examination, and re-evaluation applications.”126 The key role of the Safety Division is to amass adverse
drug reaction data and make certain the adequacy of the Japanese government’s measures aimed to protect
patient safety.127







26c) The Health Policy Bureau
The Oﬃce of Industry Research and the Research and Development Division of the Health Policy Bureau
are the Ministry’s two primary oﬃces relating to the drug approval process. The Research and Development
Division oﬀers guidance for and supervision of the KIKO concerning basic research, the promotion of research,
and the promotion of orphan drug development.128 “The Oﬃce of Industry Research collects and publishes
information on pharmaceutical companies and the entire pharmaceutical industry (and related companies),
and supports the drafting of industrial policies by the Health Policy Bureau.”129 Additionally, it functions as
a forum for discussion of information and opinions through consultations with the industry.130 According to
Japanese law as of April 1, 2000, anybody has the right to request disclosure of documents held by national
governmental agencies. As a result of this law, the MHLW must release the contents of its reviews (new
drug approval information dossiers, etc.). Companies commencing clinical development activities in Japan
are encouraged to obtain as much relevant information to their development program as they can through
this oﬃce.131
d) The National Institute of Health Sciences’ Pharmaceuticals and Medical Devices Evaluation
Center
The National Institute of Health Sciences (NIHS)132 oversees the Pharmaceuticals and Medical Devices
Evaluation Center (PMDEC). Furthermore, the NIHS carries out tests and research on drugs, quasi-drugs,





132The National Institute of Health Sciences was formerly known as the National Institute of Hygienic Sciences. Id. at 8.
27ination and reevaluation of approved drugs and medical devices.”133
e) Pharmaceuticals and Medical Devices Evaluation Center (Evaluation Center)
Established in 1997, the Pharmaceuticals and Medical Devices Evaluation Center (PMDEC) plays the main
role in the drug review and approval process. “It is responsible for conducting the reviews required for ap-
proving the manufacturing o(f) import drugs, quasi drugs, cosmetics and medical devices and for conducting
the re-examination and re-evaluation of drugs and medical devices.”134 Additionally, it is in charge of accel-
erating and improving the expertise accessible for new drug review drugs and for the general strengthening
of the review system.135
The Evaluation Center consists of 5 main divisions, four of which are therapeutic area-speciﬁc evaluation
divisions that are responsible for conducting NDA reviews and for re-examining and re-evaluating approved
drugs. The following are the Evaluation Center’s divisions: The Planning and Coordination division, which
consists of the oﬃce of General Aﬀairs and the Oﬃce of Information; Division I, which handles antibiotics,
chemotherapeutics and anti-cancer drugs; Division II, which handles cardiovascular drugs, anti-allergic drugs
and urogenital drugs; Division III which handles biological products, blood products, radio-pharmaceuticals,
generic prescription drug products, over-the-counter drugs, quasi drugs an cosmetics; and Division IV which





28f) The Organization for Pharmaceutical Safety and Research (KIKO)
The Organization for Pharmaceutical Safety and Research is also known as the KIKO, meaning “Drug Or-
ganization.” The KIKO is responsible for administering the Adverse Drug Reporting (ADR) Relief Law and
for monitoring industry compliance with Good Laboratory Practice (GLP) Provisions and Good Clinical
Practice (GCP) Standards. Additionally, the KIKO provides assistance to companies in the designing of
orphan drug development programs.137
When conducting GLP compliance inspections, the KIKO usually asks for the assistance of the appropriate
regional Perfectural Oﬃce. Approximately two or three GLP inspections per year are performed outside of
Japan, in countries with which Japan does not have a reciprocal GLP agreement.138
Beginning in April 1997, the KIKO began oﬀering fee-based consultation services for the planning and con-
duct of clinical studies. Furthermore, they reviewed clinical study protocols and the validity of data attached
to the pharmaceutical marketing authorization applications.139 All documents generated during these com-
munications are attached to the New Drug Application and will be considered part of the application.140
While drug sponsors are advised to meet with the KIKO as early as possible in order to receive its input on
the development plan before signiﬁcant time and resources have been invested in it, the fee charged by the
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292. Japan’s Drug Development and Approval Process
a) Pre-clinical testing:
As in the United States and the EU, the safety of new clinical studies to be conducted in Japan must be
backed by animal toxicology studies before they are initiated.143 For many years, the required pre-clinical
studies have been based on Japan’s Guidelines for Toxicity Studies Required for Applications for Approval
to Manufacture or Import Drugs.144 As a result of to ICH initiative, however, Japanese authorities have
modiﬁed many of their own non-clinical testing requirements and guidelines to harmonize them with new
non-clinical, or safety, guidelines released by the ICH. In other cases, ICH guidelines have replaced Japanese
guidance documents completely.145
“Based upon ICH agreements implemented to date, the non-clinical studies necessary to support initial
and subsequent clinical studies on Japan include single does toxicity studies, repeated dose toxicity studies,
reproductive and developmental studies, genotoxicity studies, skin sensitization studies, and skin photosensi-
tization studies. For drugs that present special concerns or are intended for a long duration of use, a sponsor
must assess carcinogenic (carcinogenicity studies) potential. Typically, however, carcinogenicity studies need
not be completed prior to the drug’s ﬁrst exposure to man. The recommended duration of the repeated dose
toxicity studies usually is related to the drug’s indication and proposed duration of use, as well as the scale
of the proposed clinical trial.”146
The primary objective of non-clinical safety studies is to provide suﬃcient information to support the se-
lection of the initial human dose and the safe duration of exposure in initial clinical studies. These studies
143Id. at 10.
144Notiﬁcation No. 718, dated February 15, 1984, subsequent revisions on September 1989 and November 1999. Id. at 11.
145Id. at 17.
146Id. at 12.
30should also make available information about the experimental drug’s physiology and toxicological eﬀects.147
Additionally, this data will assist in preventing and understanding adverse events in clinical trials.148
Regardless of the country in which the pre-clinical studies are performed, particular key safety studies must
comply with Good Laboratory Practice (GLP) standards.149 For those studies to which GLP applies, the
pre-clinical testing facilities will be subject to GLP compliance inspections.150 The KIKO conducts these
reviews after an application is submitted. Based upon their ﬁndings, a facility will receive one of three
ratings:
1) Class A: Compliance with GLP
2) Class B: Some improvements are possible, but the eﬀects of non-compliance on the data’s reliability are
not considered signiﬁcant (improvements are encouraged)
3) Class C: Non-compliance with GLP151
The MHLW will accept the test results and use them in the pending application review if the testing facility
receives a Class A or Class B rating.152 Japan’s GLP requirements also apply to non-clinical data generated
in foreign countries. Mutual acceptance of GLP inspection results and data from several countries is provided
through the bilateral agreements. Countries with such bilateral agreements with Japan include Switzerland,
the United Kingdom, Germany, France, Holland and Sweden.153








31Once satisfactory animal and in vitro data has been collected and analyzed, the drug developers must ﬁle
a Clinical Trial Notiﬁcation (CTN) with the MHLW before commencing human clinical trials. Rather than
a formal request for government approval, the CTN is a notiﬁcation. In spite of this, the drug developer
cannot initiate the studies put forward in the CTN until 30 days after the regional Prefectural Oﬃce receives
the CTN. Moreover, before initiating the studies, the drug developer must resolve any signiﬁcant questions
that arise during the Koseisho’s review.154
The conventional CTN is a brief document addressing the following areas:
♣
“Ingredients and quantities of the trial drug;
♣ Method of manufacturing for the trial drug, including test results;
♣ Anticipated indications and eﬀects of the trial drug;
♣ Anticipated dose and route of administration of the trial drug;
♣ Purpose, design, and period of the trial;
♣ In cases in which the trial sponsor is not domiciled in Japan, the name and address of the in-country
caretaker;
♣ Name and address of each institution involved in the trial, the names of the physicians responsible for
performing the trial, and the anticipated amount of the trial drug can be delivered (the drug must be delivered
154“Initiation” is deﬁned as the shipment of drugs to the investigational unit. Id. at 29.
32directly to each institution by the sponsor, and the exact amount and date of delivery must be recorded); and
♣ A justiﬁcation for any fee charged for the clinical trial drug.155
c) Clinical Trials in Japan
Clinical trials must conform to Japan’s Good Clinical Practice (GCP) standards.156 These standards were
revised in April of 1997. Prior to 1997, the clinical trials were dominated by physician-investigators.157
Under this system, the sponsor’s role was limited to providing clinical trials support, administration, and
data analysis. Similarly, Japan’s regulatory agencies provided only administrative reviews of development
programs and a ﬁnal sign oﬀ on scientiﬁc reviews.158 Furthermore, pre-1997 clinical trials often employed
“soft” endpoints based on physician implemented and subjective scales of eﬃcacy, safety, and usefulness. 159
“During the 1990s, Japan’s drug development system evolved considerably—from an idiosyncratic system
unique to Japan to a more harmonized and ICH-compatible system.160 Under the April 1997 revisions,
virtually all of the elements of the ICH-promulgated GCP standards were incorporated into Japan’s drug
development system.161
d) The Japanese NDA
A drug is deﬁned as a “new” drug if “at the time of application for a manufacturing or import approval, it








33or the planned dosage form) from those already approved in Japan.”162
In advance to marketing a new drug in Japan, a sponsor must submit and obtain government approval for
a new drug application (NDA) and either a manufacturing plant license, if the drug is to be manufactured
in Japan, or an import license. Like the United States and Europe, Japan evaluates its NDAs based on the
drug’s quality, safety and eﬃcacy.163 A typical Japanese NDA contains the following:
1) Outline of data submitted
2) Application form
3) Proposed packet insert
4) Copies of certiﬁcates (primarily compliance statements)
5) Application Summary (including appendices for speciﬁc listing of study information)
6) List of data submitted
7) Data
8) Other references as necessary164
The most important scientiﬁc requirement in the Japanese NDA is the Application Summary, also known as
Gaiyo (synopsis). It functions as the chief application reference throughout the government’s review.165 The
Gaiya should concisely sum up the main points pertaining to the quality, safety, and eﬃcacy of the drug,
and these points must be based on, and referenced back to the documents appended to the application.166
ICH eﬀorts, however, are bringing about signiﬁcant changes to marketing dossiers in Japan. “Like the






34common technical document (CTD) format.” Up until July 2003, Japan will be going through a transitional
period. Up until that time, applicants seeking drug approval in Japan will have the choice of submitting
their marketing dossiers in the regular Japanese NDS format or under the CTD format. After July 1, 2003,
however, Japan will require that the CTD format be used in all applications.167
e) The NDA Review Process
The NDA review process begins when the applicant submits an NDA to the pharmaceutical section of the
local Perfectural Government Oﬃce. For foreign companies, this would be the oﬃce responsible for the dis-
trict in which the company’s in-country caretaker is located. Upon receiving an NDA, the local Perfectural
Government Oﬃce ensures that all of the required documents are included in the submission. After the com-
pany addresses any issues raised during this administrative review, the local Perfectural Government Oﬃce
then submits the application to the Pharmaceuticals and Medical Devices Evaluation Center (PMDEC).168
The Evaluation Center then forwards the application’s clinical and non-clinical data ﬁles to the KIKO, which
reviews the data’s reliability and ensures that that the studies producing the data complied with GCP and
GLP requirements. Once the KIKO validates the reliability of the data and the studies, the Evaluation
Center begins its review of the new drug’s eﬃcacy, safety, and quality.169
As of November 2000, the evaluation process put into practice by the PMDEC involves the following steps:
1) An interview involving a sponsor presentation, queries and data checks; 2) A team review involving meet-
ings with members of KIKO and advisory experts; 3) An additional interview with further inquiries and
data checks; 4) An Initial report is issued; 5) A specialists meeting with at least three clinical experts; 6)




35specialists meeting; 8) A second report is issued; and ﬁnally 9) A second report is forwarded to the PMSB’s
Evaluation and Licensing Division.170
Following this process, a report is submitted to the Pharmaceutical Aﬀairs Section of the PAFSC for review.
Subsequent to this review, the report is forwarded to the MHLW, where the Minister grants the new drug
approval.171 At this point, the MHLW prepares a New Drug Approval Information Package (NAIP) based
on the review data. The NAIP is published so as to ensure that accurate information obtained during the
review process involving the eﬃcacy, quality and safety and that is required for the proper use of the drug,
can be supplied to medical professionals and medical institutions.172
While no oﬃcial mechanism exists for a sponsor to appeal the Japanese government’s refusal to approve
a license to manufacture, sell or import a drug,173 the applicant may request that the MHLW reevaluate
the usefulness and necessity of the product.174 The drug company may supply new analysis of the already
submitted data, but may not submit new data. Consequently, the chance of success for a previously rejected
application is poor.175
3) Acceptance of Foreign Data
Japan’s stance on the employment of foreign clinical data to support new drug approvals has changed
substantially over the past few years. In 1998, Pharmaceutical Aﬀairs Bureau (PAB) Notiﬁcation No. 660







36672 on the bearing of ethnic factors on the acceptability of foreign data. Under Notiﬁcation 660, only
safety data derived from foreign clinical trials could be employed to back approval in Japanese NDAs, while
eﬃcacy and clinical pharmacology data could be received only as supportive, non-pivotal data for a product’s
registration. However, according to the latest notiﬁcations (Notiﬁcations 672 and 739), which are based on
ICH guidelines, data from foreign clinical trials can be used, provided that they: (1) are found to have
resulted from studies compliant with Japanese GCP standards; and (2) the drug’s eﬀects are not likely
to be aﬀected by ethnic factors. If it is considered necessary as a result of this review, the sponsor will
conduct a study, called a “bridging study,” to show whether the study results in non-Japanese subjects can
be extrapolated to the Japanese population. If it can be so extrapolated, the foreign data will be accepted
in the Japanese NDA.176
The fact that the MHLW’s is willing to allow foreign data in NDAs signiﬁes a notable change in Japan’s
drug development system. Currently, a number of drug development programs have, through the KIKO
consultation process, requested the assessment of their plans to include foreign data in a Japanese NDA.177
Many of these companies are preparing to conduct bridging studies. One obstacle in this new environment is
that Japanese regulators or investigators have not put forth a clear deﬁnition of what constitutes a bridging




37II. HISTORY OF PHARMACEUTICAL HARMONISATION
1. Early History of Harmonization
Since 1965, the European Economic Community (EEC), now the European Union, has sought to harmonize
pharmaceutical regulation. By 1975, the EEC had established the Committee for Proprietary Medicinal
Products (CPMP). The aim of the CPMP was, and continues to be, to “facilitate the adoption of a com-
mon position by individual licensing authorities.”179 By 1985, the EEC had instituted a timetable for the
elimination of obstacles to pharmaceutical trade within the community.180 Concurrently, the EEC began
bilateral discussions on possible pharmaceutical harmonization with both Japan and the United States.181 It
was not until 1989, at the WHO Conference of Drug Regulatory Authorities (ICDRA) in Paris, that all three
parties convened together to make speciﬁc plans for trilateral harmonization.182 In April 1989, at a meeting
hosted by the European Federation of Pharmaceutical Industries and Associations in Brussels, the ICH was
formed.183 ICH headquarters was later set up in Geneva, Switzerland, with the International Federation of
Pharmaceutical Manufacturers Association taking over administrative duties for the ICH.184
2. Forces Behind Harmonization
“The urgent need to rationalize and harmonize regulation was impelled by concerns over rising costs of
179Joseph G. Contrera, The Food and Drug Administration and the International conference on Harmonization: How Har-
monious Will International Pharmaceutical Regulations Become?, 8 ADMIN. L.J. AM. U. 927, 939 (1995).
180Id.
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zation: A Strategy to Remove Technical Trade Barriers for Pharmaceutical Products, The International Commercial Diplomacy
Project, at http://www.commercialdiplomacy.org/ma projects/cortez.htm (Spring 2002).
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38health care, escalation of the cost of R&D and the need to meet the public expectation that there should be
a minimum of delay in making safe and eﬃcacious new treatments available to patients in need.”185 The
governments of several European countries and the United States were experiencing increasing consumer
demands for improved access to new drugs.186 The FDA in particular, was under continual pressure both
from inside and outside the agency to be more eﬃcient187
In addition to the continual pressure for greater eﬃciency in the drug approval process, several other major
forces are at work behind international drug harmonization as envisioned by these three regions. The in-
creasingly international character of products and industries that the FDA regulated,188 the need for better
global market access for Japanese pharmaceutical products,189 economic globalization and a growing eco-
nomic interdependence between the regions have also been forces behind the move toward harmonization.190
Moreover, provisions of the World Trade Organization agreements such as the Agreement on the Application
of Sanitary and Photo sanitary Measures and the Agreement on Technical Barriers to Trade, encourage
harmonization.191
An additional force behind the movement towards international pharmaceutical harmonization is a border-
less Europe under the EU.192 The move towards a borderless Europe may also serve to explain the reason
for the FDA’s support of the ICH. “Once commentator recently queried whether FDA’s participation in ICH
is due, at least in part, to a fear of losing its stature as the world’s preeminent regulatory body for drug
approval.”193 The FDA has always held itself out as the “gold standard” in this respect largely because of
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39its authority over the largest equivalently regulated market for pharmaceuticals. The size of the U.S. market
ensured that drug manufacturers would establish development and testing programs around the demands
of U.S. regulators. “In this light, FDA assumed that harmonization meant, in essence, conformity to the
U.S. model. For many years this was true, and Europe and Japan followed the United States’ lead.194 The
EMEA, however, now oversees a consistent regulatory system over a signiﬁcantly larger population than that
of the U.S. This creates the possibility of the EMEA displacing the FDA as the de facto regulatory standard
setting agency for drug approval.195
3. Potential Beneﬁts from Pharmaceutical Harmonization
There are numerous potential beneﬁts to the pharmaceutical industry that could result from harmonization.
a) Timesaving
Perhaps the strongest impact of harmonization will be the resultant saving of time. Inconsistent national
standards create lag time between product development and distribution thereby increasing industry costs
including loss of sales, loss of revenue from a decrease in eﬀective patient life, loss of working capital, and loss
of staﬀ costs for processing multiple applications. Such timesavings will provide earlier access to innovative
therapies. This will help save more lives and will also be more proﬁtable to companies.196
b) A Reduction in the Cost of Drug Development
FOOD & DRUG L.J. 203, 207 (1997).
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40Harmonization will allow drug companies to avoid duplicative tests in states that are parties to the ICH
agreement. Furthermore, it will simplify preparation of application dossiers197 and will lessen the costs
associated with guiding drugs through the process of regulatory review for each country’s market. This will
provide companies with great cost savings. These savings in costs will be beneﬁcial for the drug companies
and consumers.198 Companies will be able to shift these cost savings into more research and development of
new drugs.199 Consumers will beneﬁt from the development of new drugs. Furthermore, as the cost of drug
approval declines, more pharmaceutical companies may enter the market, which will increase competition
among drug companies and could result in a decline in drug prices. In addition, it will allow smaller drug
companies to enter the market. Multinational companies bear extremely large expenses in learning the
various regulations of each market in which they operate. “This capital-intensive process eliminates small
drug companies” from the development of new drugs.200
c) Improvement of World Health
Harmonization will ideally make the world safer, and thereby reduce the spread of disease within and between
nations. Health concerns of nations are interrelated. Most developing countries use a certiﬁcation scheme,
which allows use of the drug if it has been approved for use in the nation that developed it.201 Hence, they
are relying on the regulatory processes of the developed countries. The certiﬁcation scheme is problematic
when drugs are received from nations whose regulatory process is too lax (because dangerous and ineﬀective
drugs could be marketed). If pharmaceutical regulation is harmonized such that the regulatory processes
of developed nations ensure the eﬃcacy and safety of drugs, the developing nations will be better oﬀ.
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41Furthermore, harmonization will hopefully eliminate repetitive testing and requirements such that eﬀective
treatment will be able to reach developing nations with less delay.
While improving health in the Third World is in and of itself a beneﬁt of harmonization, it is also beneﬁcial
in that it may reduce the spread of disease between nations. When inferior and ineﬃcacious drugs are
used by a nation, this could very well have an impact on the entire world. “For instance, antibiotics
on developing countries are frequently used in inadequate dosages and for too short a treatment period,
resulting in inadequate treatment for the local population and creating drug-resistant strains of bacteria.
These bacterial become impossible to treat as they invariably spread throughout the world.”202 The health
of nations is also interrelated when one considers the health care implications for citizens of the developed
world who travel abroad.203
Moreover, pharmaceutical harmonization will improve information transfer between countries on public
health issues.204
d) Advance International Trade Such that the U.S. will Can Export More
Statistics indicate that U.S. drug companies cannot remain proﬁtable by marketing their products exclusively
within in the U.S. Because of the long approval process in the U.S. and the notoriously strict regulatory
climate, U.S. pharmaceutical companies have increasingly been performing clinical trials and original product
introductions in foreign markets. Because the consumer market in the EU is now larger than the consumer
market in the U.S. and because the approval process is generally considered to be faster in the EU, this
provides large incentives for U.S. ﬁrms to relocate their operations oversees if harmonization fails. Under a
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42harmonized system, the U.S. export position will improve. U.S. drug companies will perform tests at the
IND stage, and then will be able to submit a common data package to each of the regulatory participants.
Once the foreign regulatory authorities approve the new drugs, the drug companies will be able to export
the drugs from the U.S.205
III. THE INTERNATIONAL CONFERENCE ON HARMONISATION
1. Overview
The International Conference on Harmonization (ICH) is a tripartite eﬀort between the United States, the
European Union and Japan to harmonize regulatory requirements for the testing, application and approval
process of pharmaceutical medications.206 Although the ICH is open to worldwide participation, it focuses
on harmonization among the U.S., EU and Japan because they account for 75% of the world’s pharmaceutical
market and generate 90% of all pharmaceutical research.207
The ICH has two primary goals: 1) to reduce the costs of drugs to consumers by minimizing regulatory
problems associated with the need to comply with diﬀering requirements of each 2) increase the safety,
eﬃcacy, and quality of pharmaceuticals208
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432. The Mechanics of the ICH Process
a) Members
The United States, the EU, and Japan each have two active parties in the ICH. One party represents the
government regulators and the other represents industry manufacturers. The two parties representing the
U.S. in the ICH are the U.S. Food and Drug Administration and Pharmaceutical Research and Manufacturers
of American (PhRMA). The EU is represented by the European Commission and by the European Federation
of Pharmaceutical Industries’ Associations. Finally, the Ministry of Health, Labor and Welfare (MHLW) and
Japan Pharmaceutical Manufacturers Association (JPMA) are the representatives for Japan. “In addition
to the six participating parties, ICH also includes three observers who act as a liaison between ICH and
non-ICH countries and regions. The three observers are the WHO, the European Free Trade Area (EFTA),
and Canada.”209
b) Structure
The structure of the ICH is comprised of four main groups: the Steering committee, the Expert Working
Groups, the Secretariat, and the Coordinators.210
The Steering Committee: The steering Committee is composed of two representatives from each of the 6
member parties and one representative from each of the three observing parties. The Steering Committee
establishes ICH policies and procedures and chooses topics for harmonization. Additionally, the committee
209Alessandra Cortez, Introducing the International Conference on Harmonization Guidelines Into the World Trade Organi-
zation: A Strategy to Remove Technical Trade Barriers for Pharmaceutical Products, The International Commercial Diplomacy
Project, at http://www.commercialdiplomacy.org/ma projects/cortez.htm (Spring 2002).
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44supervises the advancement of harmonization initiatives.211
Expert Working Groups: The Steering Committee appoints an Expert Working Group (EWG) to each of the
technical topics selected for harmonization. EWGs represent each of the six members parties, the observers
and any other relevant parties (such as the generic drug industry, pharmacopoeias etc.). The groups consist
of industry specialists on the topics discussed, and group members are nominated by each of the six parties.
EWGs do not have a ﬁxed membership. Rather, they are involved for the timeframe in which their relevant
topic is being discussed and/or reviewed.212
The Secretariat: The Secretariat prepares for and documents all of the ICH meetings. Furthermore, they
serve as links with any speakers who attend those meetings.213
The Coordinators: The coordinators serve as the primary contact between the Secretariat and the six member
parties. Additionally, they make certain that ICH documents are properly distributed.214
c) The Process
The ICH process involves ﬁve phases. First, the ICH steering committee selects topics for harmonization
based on advice from the Expert Working Groups. In this ﬁrst phase, the Expert Working Groups draft a
preliminary statement, which is forwarded to the Steering Committee. The draft includes guidelines, policy
statements, recommendations, and points-to-consider. In phase 2, the Steering Committee forwards the
draft to the three-member regulatory agencies for formal consultation for a 6-month commitment period. In





45from the member regulatory bodies. Upon this revision, the EWGs review the amended draft and send it
to the Steering Committee for adoption. In phase four, the Steering Committee endorses the ﬁnal draft and
recommends it for adoption by the regulatory bodies of the US, the EU and Japan. Finally, in Phase 5, the
three regulatory bodies incorporate the recommendations into their domestic regulations.215
2. Implementation of Harmonization In the Three ICH Regions
ICH guidelines, by themselves, have no authority. “The consensus reached through the ICH has neither the
force of an international accord nor a treaty; it represents a ﬁrm political commitment on the part of the
concerned governments.” Each regulatory agency will put into operation its own legislation to make active
the guidelines determined at the ICH meetings.216 Because there is no system to ensure implementation of
the agreements and guidelines, implementation is likely to be a slow process.
a) The United States
The greater part of the FDA’s administrative rules consist of “regulations” and “guidelines.” Regulations
signify legal requirements, and therefore take years to formulate. On the other hand, guidelines signify
general principles, which the FDA develops in shorter time frames. If a new drug producer adheres to the
requirements recommended by the guidelines, the FDA must accept the data. If, however, the drug producer
employs a diﬀerent method, the FDA may reject the data.217
Harmonization authority is a part of the FDA’s wide-ranging authority for regulations, approvals, enforce-
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46ment and other activities. FDA can undertake the construction of “regulations” that harmonize its reg-
ulations with an international standard, so long as the resulting regulation is consistent with the statutes
the agency administers. Thus, International harmonization is achieved in the US under the Administrative
Procedure Act and Agency Administrative procedure requirements.218
However, where a binding requirement is not made, as is the case for most of the ICH guidelines, the process
is less rigid.219 When Step 2 or step 4 has been reached, the FDA then publishes a notice with the full
text of the ICH guidance in the Federal Register for public comment. After considering comments, within
the Agency and in collaboration with international partners, FDA publishes a ﬁnal guidance document in
the Federal Register. Notices for Step 2 guidances contain a date for receipt of written comment. Step
4 guidances are available for use in the date they are published in the Federal Register.220 “In addition
to seeking public input through publications of various materials, the FDA provides periodic workshops to
discuss the ICH process.”221
b) The European Union
Once ICH guidelines have reached Step 2 or Step 4 of the ICH process, they are submitted to the CPMP for
endorsement. The CPMP decides on the length of time that is appropriate for consultation with interested
parties (usually 6 months) and the EMEA publishes and distributes the Step 2 guidelines for comments. At
step 4, the guidelines are endorsed by the CPMP and a timeframe for implementation is established (also
usually 6 months). The guidelines are subsequently published by the European Commission in Volume III
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47of the Rules Governing Medicinal Products in the European Union.222
c) Japan
The Japanese Parliament acts only after the Japanese government agencies, political parties, and business
insiders reach a consensus. Usually, an industry committee draws up the preliminary product standard
and presents it to the appropriate ministry, although the reverse is also possible. In either situation, the
business insiders and the government generally arrive at an agreement before a draft standard is oﬀered
for public comment. While a great deal of information regarding regulatory development has been made
public in recent years, it is still unclear as to who speciﬁcally directs the drafting of the standards. While
the Japanese Ministry of Health and Welfare could issue its own rules implementing the ICH principles, the
government tends to seek voluntary cooperation from the industry (they tend to choose “guidelines” over
“rules”). 223
Once Step 2 or Step 4 are reached, the ICH texts are translated into Japanese. Subsequently, Pharmaceutical
and Medical Safety Bureau (PMSB) Notiﬁcation for the promulgation or consultation of guidelines written
in Japanese is issued with a deadline for comments in the case of consultation drafts, or an implementation
date for ﬁnalized guidelines.224
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48IV. Barriers to Achievement of the Goals of the ICH
There remain some considerable barriers that need to be overcome before the harmonization of international
pharmaceutical regulations can truly be achieved.
1. Lack of Central Enforcement Authority
The primary barrier to harmonization facing the EMEA and the ICH as a whole is the lack of a central
enforcement authority empowered to impose its actions on the other countries.225 Individual countries’
legislatures continue to have ultimate control of implementation. “Without enforcement procedures built
into the central system to assure compliance, members countries retain a potential “veto” which in turn
jeopardizes the entire system.” This is particularly applicable to the U.S. where there is strong ambivalence,
both by the legislature and FDA.226
A lack of enforcement procedures also means that the FDA will go on inspecting foreign manufacturers for
compliance with Good Manufacturing Practice and Good Clinical Practice Standards. “Ideally, enforcement
would allow a central body to audit practices by all manufacturers and provide independent assurance that
ICH adopted standards will be maintained without the need for inspection by each country’s own regulatory
agency.”227
2. U.S. Ambivalence
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49While supporting the ICH in theory, the FDA’s approach to implementing ICH guidelines “has failed to
meet the standards for openness and balanced representation that are necessary for ready acceptance of the
ICH standards.”228 “By its own admission, the FDA is pursuing harmonization as a secondary eﬀort while
maintaining its primary eﬀort of domestic drug control.”229 Several observers have commented that the
U.S.’s idea of harmonization is that its regulations should apply.230 Two points of concern seem to underlie
FDA’s ambivalence towards harmonization. One worry is that the FDA, which is normally accustomed to
having a great deal of control, will be subjugated to the will of the international community.231 Congress,
which ultimately shapes a great deal of FDA policy, “is wary of the potential negative eﬀects of ceding a
large measure of control to a foreign entity.”232 The second point underlying U.S. ambivalence is the FDA’s
fear of compromise of safety and eﬃcacy standards and the FDA’s general distrust of foreign data.
The U.S., not at ease with relying on what it may sense is unconﬁrmed and uncontrolled foreign clinical and
manufacturing practices, may perhaps continue to develop Memoranda of Understanding (MOU). MOUs are
one of the ways the FDA is attempting to continue oversight of the drugs used by the American populace.
MOUs allow the FDA to impress its more stringent standards on foreign countries and also serve to grant au-
thorization for foreign inspections. “Eﬀectively this adds another layer of inspection which potentially slows
the overall process through unnecessary redundancy. This result negates the purpose of harmonization.”233
3. Constitutional Diﬃculty
One obstacle within the United States confronting the movement towards international harmonization is
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50the Constitutional diﬃculty with delegating decision-making authority to a foreign government. The non-
delegation doctrine limits the ability of Congress to delegate to administrative agencies the legislative powers
vested in it by Article 1 of the Constitution. However, the Supreme Court has rarely ever invalidated on
Article 1 grounds acts of Congress which delegated authority to the President or any administrative agency.
The Supreme Court has, however, set limits on Congress’s ability to delegate authority beyond the bounds
of the federal government. Despite the fact that the Supreme Court has never explicitly addressed the
issue of delegation to foreign powers, constitutional concerns may apply to an agreement that allowed a
foreign regulatory body to bind the FDA to a particular decision. For example, some scholars have argued
that Article 43 of the United Nations Charter, which authorizes the UN Security Council to carry out an
agreement whereby U.S. forces would serve under foreign command, might violate Congress’s Article 1 power
to declare war.234
Case law suggests that the non-delegation doctrine could be overcome as long as the FDA retained the ﬁnal
authority to object particular new drugs.235
4. Cultural and demographic diﬀerences between the Three ICH Regions
a) Diﬀering Attitudes Toward Health and Medicine
There seems to be a general unwillingness of Americans to accept any level of risk regarding pharmaceutical
products and, that American attitudes about risk are diﬀerent from those of other countries.236 “A study
be Sheila Jasanoﬀ revealed variances between citizens of Britain and the United Sates in their attitudes to-
ward four diﬀerent types of environmental risk. Jasanoﬀ found that in Britain, scientists and other decision
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51makers are certain to recognize a risk only when there is persuasive evidence of actual harm... whereas in
the United States a risk may also be acknowledged where there is a no direct proof of injury to the public.
This cultural diversity of attitude may be compounded in the realm of personal illness—especially terminal
disease—where the very notion of ‘risk’ becomes indeterminate and subjective.”237
Another matter in which attitudes diﬀer in the three regions is in the area of informed consent. This is an
obstacle to the development of pharmaceutical standards, particularly in the conduct of clinical trails.238
The U.S. seems to put a stronger emphasis on informed consent than do Japan and the Europe. Japanese
physicians have what Americans view as a ‘paternalistic’ attitude towards informed consent.239 For example,
it is often the case that many patients are not told that they are being placed on an experimental drug. The
EU tends to favor medical progress over fully informed consent. They tend to lie somewhere in the middle
of the spectrum between the U.S. and Japan.240
Additionally, western manufacturers have refrained from conducting clinical trials in Japan because of their
belief that doctors there are frequently unwilling to follow protocols precisely.241 “In Japan, when admin-
istering a pharmaceutical, the doctor may decide on his own to mix it with dried herbs and roots from the
local area to increase its eﬀectiveness.”
Identiﬁable cultural diﬀerences also exist with respect to moral attitudes about certain drug products (e.g.,
the European ‘abortion’ drug RU-486, or pharmaceuticals developed form the use of fetal tissue research).
There also may be diﬀering attitudes toward intensive animal testing.242
b. Diﬀerent Physiological Reactions to Drugs
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52An additional barrier to the acceptance of one another’s foreign data arises from cultural and demographic
diﬀerences between the U.S., Europe, and Japan. Certain medical evidence suggests that diﬀerent racial and
ethnic groups have various reactions to pharmaceutical products, such that a drug that is safe and eﬀective
in one population groups might be less so in other racial or ethnic groups.243 If it is the case that diﬀerences
exist in the way diﬀerent ethnic groups react to certain drugs, then a research protocol which excludes groups
may miss not only the side eﬀects of that particular drug, but may result in a signiﬁcant positive eﬀect being
missed altogether.244
Additionally, there are culturally driven ethnic factors that play a crucial role in the determination of drug
equivalence as well as eﬃcacy. These factors include diet, smoking habits, use of alcohol, exposure to pollu-
tion, amount of daily sunshine, socioeconomic status, and compliance with prescription drug regimens.245
5. Political barriers
Several authors have noted the close relationship of drug regulatory activities and public policy in any given
country. Surrendering this control to a central agency would prove essentially unworkable for many states,
which view regulation of drugs as synonymous with national sovereignty. In large part, this has led to the
structuring of the ICH without any central enforcement capabilities.246
6. Patent Laws
“There is strong evidence that the vitality of any modern health care system is directly dependant upon a
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53strong intellectual property regime.” Presently, there is a great dissonance in patent laws around the world.
Furthermore, there appears to be little potential for harmonization of patent laws. The chief impediment
in the sphere of patents is the United State’s resistance to implementation of a “ﬁrst to ﬁle” system for
patent recognition. In contrast to the “ﬁrst to ﬁle system,” which is the de facto international standard, the
United States uses the “ﬁrst to invent” system. While it is acknowledged that a change by the U.S. to the
ﬁrst to ﬁle system would necessitate statutory amendment of a system supported by 200 years of case law in
the U.S., most U.S. companies doing business internationally are currently working under the “ﬁrst to ﬁle”
system with no diﬃculty.247
7. Mission creep
Another impediment to harmonization of pharmaceutical regulation is “mission creep.” “Mission creep” is
an expansion of original objectives to include less focused and less realistic goals. Recognition of a signiﬁcant
need for international collaboration has led some to advocate a sort of “mission creep.” For example, Peter
Southerland, former European Community Commissioner for Ireland, has urged the European Federation
of Pharmaceutical Industries’ Association to be more aggressive in demanding that non-drug health care
technology and treatments be subjected to the same level of regulatory scrutiny as the pharmaceutical
industry.248 Standards for such varied things as lawnmowers and electromagnetic radiation, which are
beyond the scope of the ICH, are being developed under the general umbrella of the Mutual Recognition
Agreement.249 Although consumer safety is the common theme for these products as it is for with drugs,
the means and methods of deﬁning and assuring it diﬀer vastly, thus limiting the potential for optimal
determination of issues speciﬁc to drugs.
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548. Global protection of human subjects
There are no international treaties governing experimentation on humans. The trend toward greater accep-
tance of foreign data and the eﬀorts to harmonize drug regulations can only lead to more research being
conducted abroad. To what extent can the countries involved be assured that this research is being con-
ducted ethically? National regulations have very little extra-territorial eﬀect and there are no international
treated governing experimentation on humans.250
9. Harmonizing Upward v. Harmonizing Downward
An additional problem faced by both the EU and the ICH as a whole is that nations with the most rigorous
standards are pushing to “harmonize upward” whereas nations with the least stringent standards are pushing
to “harmonize downwards.” Both a “race to the top” and a “race to the bottom” would result in an
unfavorable outcome. A “race to the bottom” forgoes health and safety standards in favor of freer movement
of goods, whereas a “race to the top” would appear to defeat the very objectives of harmonization—reducing
the cost of drug development, speeding the process from development to market, and making drugs available
to the consumer251
V. THE IMPACT OF REGULATORY COOPERATION
1. ICH Accomplishments
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55Despite the signiﬁcant barriers to harmonization, numerous accomplishments have been made under the
auspices of the ICH. The principal achievement of the conference is the willingness of all three regulatory
agencies to commit publicly to harmonization principles. The FDA’s presence at the conference was partic-
ularly striking because of their reluctance in the past to accept foreign data.252 The collaborative spirit of
the agencies was further evidenced through their agreement to a “de facto moratorium” on the introduction
of new clinical testing standards. They viewed the development of potentially inconsistent tests as contrary
to harmonization.253
In addition to this political achievement, there have also been many technical accomplishments. To date,
ﬁfty guidelines have been harmonized between the three regions.254 Moreover, they have also developed
several products and services to facilitate the harmonization process. These services are designed to help
the member parties’ manufacturers comply with ICH guidelines and to increase clarity of the guidelines.255
The main products and services developed thus far are the Common Technical Document (CTD), MedDRA,
the Electronics Standards for the Transfer of Regulatory Information and Data (ESTRI), and the Global
Cooperation Group (GCG).256 As well as discussing these products, this section will highlight some of the
important guidelines that have been harmonized.
a) The Common Technical Document
At the fourth ICH conference in July of 1997, the three parties agreed to take on the development of a common
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56technical document (CTD).257 By mid-2001, the CTD application was produced.258 The development of the
CTD is considered to be the ICH’s most signiﬁcant achievement thus far. “It is described as a harmoni(z)ed
core ‘information package’ of [clinical, pharmacology/toxicology, and quality] technical data’ that can be
submitted in the same format and with the same content to obtain marketing authori[z]ation in any of
the three ICH regions—the United States, the European Union , and Japan.”259 All three regions have
implemented a “transition period” from July 2001 to July 2003, during which companies will have the
option of submitting marketing authorization applications for any new drugs in either the conventional
regional format or the new CTD format. Once the transition period ends in July 2003, the EU and Japan
will require that marketing authorization applications be ﬁled in the CTD format and the U.S. will highly
recommend that the CTD format be used.
b) MedDRA
In order to make harmonization feasible, the ICH realized that they needed to eliminate regulatory com-
munication barriers. The ICH Steering Committee and EWGs created MedDRA, a medical terminology
vocabulary that would allow the EU, Japan, and the U.S. to use one medical language.260 “The multiple
dictionaries that were used prior to the creation of MedDRA were often incompatible with one another
and lead to communication problems when manufacturers reported their information to multiple regulatory
agencies.”261
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57c) Electronic Standards for the Transfer of Regulatory Information and Data
Because the three founding parties of the ICH are spread across the world, high-speed technology and the
Internet are the most eﬃcient means for information exchange and application processing. The ICH Steering
Committee delegated an EWG to manage the development of an electronic system for informational exchange
between manufacturers and regulatory authorities. The Electronic Standards for the Transfer of Regulatory
Information and Data (ESTRI) “covers the evaluation of encryption technologies, physical media (ﬂoppy
disks and CD-ROMS), network messaging, message formats and electronic document transfers.”262 In 1996,
the EWG selected software to handle ICH needs, and since 1997, members of the ICH have been using the
software to transfer drug reports.263
d) The Global Cooperation Group
From the onset of the initiative, members of the ICH have made an eﬀort to uphold a transparent system
of practice that would maintain all ICH guidelines and documents open to manufacturers and authorities of
all countries. In an attempt to guarantee smooth communication with non-ICH members, the ICH created
the Global Cooperation Group (GCG) to serve as an information liaison between ICH member parties and
non-ICH member parties. Additionally, the GCG produced a set of principles to be followed when handling
requests from non-member parties.264




58Another considerable accomplishment of the ICH was the adoption of an ICH harmonized Good Clinical
Practice (GCP) guidance. A consolidated ICH GCP guidance was released for comment in late 1995 and was
subsequently adopted in May 1996.265 This guidance has eliminated many of the considerable diﬀerences in
clinical trial related regulatory requirement between the three ICH regions. It has also led to the elimination
of much of the variability between the EU’s Member States.266
f) Stability testing
The members of the ICH have also materialized a set of harmonized procedures for determining the shelf
life of new drugs. The procedures, known as “stability testing,” could save money during the development
stage of the new drug and during the reexamination stage of the new drug during its lifetime.267
g) Reproductive Toxicology Studies
The testing procedures to determine whether a new drug causes birth defects and/ or aﬀects fertility will
also be harmonized.268 So far, the three ICH regions are in agreement that “all female reproduction toxicity
studies and the standard battery of genotoxicity studies should be completed before any women who are of
childbearing potential and who are not using eﬀective birth control, of whose pregnancy status is unknown,
are enrolled in clinical studies.”269
265Russell & Bremer, supra note 120, at 59.
266Lofgren & Dreessen, supra note 73, at 164.
267Jordan, supra note 1, at 493.
268Jordan, supra note 1, at 494.
269Russell & Bremer, supra note 120, at 23.
59h) LD 50 and Other Animal Testing
Additionally, accomplishments have been made in the area of animal testing. A test known as Lethal Dose
50 has been abolished. This test, which was used to determine the lethal dose of new drugs, involved
administering increasing dose of the drug to dogs and rodents until half of them died. They resolved to
stop requiring twelve-month toxicity studies involving dogs and rodents. Instead the studies will last for 6
months. These arrangements are expected to save the lives of thousands of animals in addition to saving a
great deal of money.270
i) Guideline for Safety Pharmacology Studies
In November 2000, an ICH guideline pertaining to safety pharmacology studies reached step 4 of the ICH
process. While this guideline has not yet been adopted in the United States and Japan, it has already been
adopted in the EU. This guideline provides a general direction concerning which studies are necessary prior
to the initiation of a Phase 1 study, which typically include safety pharmacology studies identiﬁed in the
safety pharmacology core battery.271
2. Evaluation of Pharmaceutical Harmonization
While some commentators have been less than optimistic regarding the movement toward global pharmaceu-
tical harmonization, noting that several factors serve as obstacles to the goal, there have been some strong
270Jordan, supra note 1, at 494.
271This battery of studies has been established to investigate the test article’s eﬀects on vital functions speciﬁcally the central
nervous system, the cardiovascular system, and the respiratory system. Russell & Bremer, supra note 120, at 18.
60indications of progress resulting from the ICH initiative (see ICH Accomplishments discussed above). It has
succeeded in arriving at agreements on topics “such as carcinogenicity testing, statistical principles in clini-
cal trials, viral safety evaluation of biotechnology products, testing of impurities in new drug products, the
duration of chronic-toxicity testing in animals, data elements needed for individual case reports of adverse
events, and non-clinical safety studies necessary to support the conduct of human clinical trials.”272 Each of
these topics had previously been controversial and dealt with diﬀerently in each of the three ICH regions.273
The Development of the CTD in particular is a grand achievement. One of the primary objectives of the ICH
“was to remove redundancy and duplication in the development and review process so that a single set of
data could be generated to demonstrate the quality, safety, and eﬃcacy of each new medicinal product.”274
This objective is becoming a reality with the development and adoption of the CTD.
Moreover, the ICH has had a huge impact on Japan’s drug approval process. Through its willingness to
implement ICH developed standards and guidelines aﬀecting both clinical and non-clinical data, Japan has
evolved considerably “from an idiosyncratic system unique to Japan”275 to a process that is more consistent
with the U.S. and E.U. market.
In fact, the impact that the ICH has had on pharmaceutical harmonization in the three regions has led
one commentator to remark that “(t)he days of confusion are over; the ever-changing local regulations are
rapidly coming to an end.”276
However, as previously noted, there are considerable barriers to complete pharmaceutical harmonization.
Health Policy is inextricably connected with cultural and societal values and as such has always been the
272Nancy J. Chew, ICH Now: Harmony at the End of the Century, 12 BIOPHARM 24, 27 (1999).
273Id.
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61focus of intense politicization by regional and national governments.277 With this in mind, it seems likely
that the individual countries will maintain ultimate veto power with regard to approval of a single drug or
drug product.278
CONCLUSION
Harmonization of the technical regulations for drug approval in the United States, Europe, and Japan is
a worthy goal. The United States, the EU, and Japan each regulate pharmaceuticals for the welfare of
their citizens. However, each country advocates its own system of laws controlling production and testing of
pharmaceuticals. Diﬀerences in the national regulations generate costs for drug manufacturers and ultimately
for consumers. Moreover, they lead to delays in the worldwide introduction of new drugs. The International
Conference on Harmonization has been a signiﬁcant eﬀort in eliminating the problems of unnecessary costs
and delays in drug approval.
With the successful completion of the ﬁrst phase of activity behind them, the ICH will move into the second
phase with the continuing commitment to increased international harmonization. Due to the success of the
initiative thus far, more interest has been generated in the initiative from regulatory and industry bodies
outside of the U.S., the EU, and Japan.279 It will therefore be increasingly important to make certain that
the goals and outcomes of the ICH are comprehensible and more widely disseminated.280
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